▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3372 by analyst upside · 2026-08-12
AMPH
Amphastar Pharmaceuticals, Inc.
Healthcare · Market Cap $869M · P/E 12.1x
ANALYST PRICE TARGET
+7.7%
implied upside to consensus target
Current Price $20.42
Consensus Target $22.0
Bull Target $30.0
Bear Target $20.0
Analysts Covering 6
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
5
Sell
1
52-Week Low $16.65
52-Week High $31.26
YTD Return -22.8%
FUNDAMENTALS
Market Cap $869M
P/E Ratio (TTM) 12.1x
Forward P/E 6.7x
EPS (TTM) $1.69
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $730M
Profit Margin 10.8%
52-WEEK RANGE
52-Week Low $16.65
52-Week High $31.26
Current Price $20.42
Bear Target $20.0
Bull Target $30.0
● Now $20.42 ● Target $22.0
TRADING DATA
Avg Volume 593K
YTD Return -22.8%
Analyst Count 6
Consensus Hold
Upside to Target +7.7%
Last Updated 2026-08-12

ANALYST SUMMARY

Amphastar Pharmaceuticals, Inc. (AMPH) is currently trading at $20.42 with a Wall Street consensus price target of $22.0, implying potential upside of 7.7% over the next 12 months. 6 analysts currently cover AMPH, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $20.0.

AMPH operates in the Healthcare sector with a market capitalisation of $869M. The stock is down 22.8% year-to-date and is currently trading near the lower end of its 52-week range of $16.65 – $31.26.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INMD +1.3%
InMode Ltd.
$870M · P/E 12.5x · Hold
TBPH +4.4%
Theravance Biopharma, Inc.
$878M · P/E 7.6x · Hold
ABUS +18.8%
Arbutus Biopharma Corporation
$923M · P/E 5.6x · Buy
RIGL +32.3%
Rigel Pharmaceuticals, Inc.
$785M · P/E 2.5x · Buy
BVS +21.3%
Bioventus Inc.
$1B · P/E 17.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AMPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-06-03 Building track record
Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2026-05-14 Building track record
Piper Sandler reit
Neutral → Neutral 2026-05-11 14% win rate (7 calls)
Needham ↓ Downgrade
Buy → Hold 2026-05-08 20% win rate (5 calls)
Jefferies ↓ Downgrade
Buy → Hold 2026-04-21 50% win rate (6 calls)
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-04-08 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-02-27 Building track record
Needham - Reiterated
Buy → Buy 2026-02-27 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
15/30
Consensus clarity
20/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →